Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Stefano Di Cecca Clear advanced filters

  • In the final analysis of a phase 1/phase 2 trial of autologous GD2-targeting CAR T cells in pediatric patients with high-risk metastatic, relapsed or refractory neuroblastoma, treatment was overall well tolerated, with an objective response rate of 66%. These findings were further supported by a case series involving the same therapy in a similar patient population.

    • Franco Locatelli
    • Daria Pagliara
    • Francesca del Bufalo
    Research
    Nature Medicine
    P: 1-11

  • In a case series of five children with treatment-refractory neuroblastoma, it was feasible to manufacture and administer donor-derived GD2-specific CAR T cells and clinical responses were seen in four patients.

    • Concetta Quintarelli
    • Francesca Del Bufalo
    • Franco Locatelli
    Research
    Nature Medicine
    Volume: 31, P: 849-860

  • B cell malignancies resistant to conventional treatments are potentially sensitive to CAR-T cell immune therapy, but its clinical applicability is limited by immune related adverse effects. Here authors show in a humanized mouse model that blocking IFNγ with the monoclonal antibody emapalumab mitigates the adverse effects of CAR.CD19-T cells without compromising their anti-lymphoma efficacy.

    • Simona Manni
    • Francesca Del Bufalo
    • Concetta Quintarelli
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-13